Proposal for a new local recurrence score in patients with recurrent malignant pleural mesothelioma.
Malignant pleural mesothelioma (MPM)
local recurrence (LR)
overall survival
score
second line therapy
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
21
10
2021
accepted:
24
03
2022
entrez:
8
9
2022
pubmed:
9
9
2022
medline:
9
9
2022
Statut:
ppublish
Résumé
Malignant pleural mesothelioma (MPM) is associated with high rates of local recurrence (LR) up to 75%. Second line treatment should be applied tailored to relapse pattern. We aimed to establish a new score for LR pattern with prognostic impact in this observational study of retrospective nature. MPM patients with LR after surgery, verified by serial imaging during follow-up visits or biopsy were included in a retrospective analysis using a new local recurrence score (LRS). We divided the thoracic cavity into six sections and calculated the LRS according to the tumor burden. We assessed the impact on survival after recurrence using cox regression model. From 2001 until 2017, 128 consecutive MPM patients with LR who underwent macroscopic complete resection (MCR) by extrapleural pneumonectomy (EPP, n=61) or by (extended) pleurectomy/decortication [(E)PD, n=67], were included in the present analysis; 104 patients received second line therapy. Patients with chest wall (CW) recurrence had the shortest survival after recurrence (9 LRS might be a useful prognostic tool in MPM patients with LR after multimodality therapy to guide second line treatment allocation.
Sections du résumé
Background
UNASSIGNED
Malignant pleural mesothelioma (MPM) is associated with high rates of local recurrence (LR) up to 75%. Second line treatment should be applied tailored to relapse pattern. We aimed to establish a new score for LR pattern with prognostic impact in this observational study of retrospective nature.
Methods
UNASSIGNED
MPM patients with LR after surgery, verified by serial imaging during follow-up visits or biopsy were included in a retrospective analysis using a new local recurrence score (LRS). We divided the thoracic cavity into six sections and calculated the LRS according to the tumor burden. We assessed the impact on survival after recurrence using cox regression model.
Results
UNASSIGNED
From 2001 until 2017, 128 consecutive MPM patients with LR who underwent macroscopic complete resection (MCR) by extrapleural pneumonectomy (EPP, n=61) or by (extended) pleurectomy/decortication [(E)PD, n=67], were included in the present analysis; 104 patients received second line therapy. Patients with chest wall (CW) recurrence had the shortest survival after recurrence (9
Conclusions
UNASSIGNED
LRS might be a useful prognostic tool in MPM patients with LR after multimodality therapy to guide second line treatment allocation.
Identifiants
pubmed: 36071779
doi: 10.21037/jtd-21-1628
pii: jtd-14-08-2835
pmc: PMC9442537
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2835-2844Informations de copyright
2022 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-21-1628/coif). WW reports that he is on the Advisory Board and a speaker of Astra Zeneca and a speaker of Covidien (Medtronic) which he received a teaching and speaker grant. IO reports receiving institutional grants from Roche and Medtronic and speakers’ fees from Roche and AstraZeneca. She is on Advisory Boards of AstraZeneca and MSD. She is Treasurer and President Elect for ESTS and in the Program Committee of ESTS, IASLC and ISHLT. The other authors have no conflicts of interest to declare.
Références
Eur J Cardiothorac Surg. 2020 Jul 1;58(1):1-24
pubmed: 32448904
Lancet Oncol. 2017 Sep;18(9):1261-1273
pubmed: 28729154
Chest. 1998 Mar;113(3):723-31
pubmed: 9515850
Ann Thorac Surg. 2010 Jan;89(1):207-10
pubmed: 20103236
J Clin Oncol. 2018 May 1;36(13):1343-1373
pubmed: 29346042
J Clin Oncol. 1998 Jan;16(1):145-52
pubmed: 9440736
J Thorac Cardiovasc Surg. 2016 Feb;151(2):478-84
pubmed: 26611742
Cancer Treat Res. 1996;82:359-74
pubmed: 8849962
Lancet Oncol. 2016 Feb;17(2):e43-e44
pubmed: 26868350
Transl Lung Cancer Res. 2017 Jun;6(3):315-324
pubmed: 28713676
Front Oncol. 2019 Sep 26;9:961
pubmed: 31616640
Ann Oncol. 2015 Sep;26 Suppl 5:v31-9
pubmed: 26223247
Eur Respir J. 2010 Mar;35(3):479-95
pubmed: 19717482
J Thorac Cardiovasc Surg. 2008 Mar;135(3):620-6, 626.e1-3
pubmed: 18329481
J Thorac Oncol. 2012 Sep;7(9):1449-56
pubmed: 22895142
J Clin Oncol. 2003 Jul 15;21(14):2636-44
pubmed: 12860938
Eur J Cardiothorac Surg. 2016 May;49(5):1516-23
pubmed: 26590183
Strahlenther Onkol. 2003 Aug;179(8):535-41
pubmed: 14509952
Clin Case Rep. 2018 Sep 04;6(10):2000-2004
pubmed: 30349716
J Thorac Cardiovasc Surg. 2013 Dec;146(6):1373-9; discussion 1379-80
pubmed: 24113019
Br J Cancer. 2014 Jul 15;111(2):220-6
pubmed: 24918816